Scientists have developed a blood test using plasma p-tau217 to predict when individuals will develop AlzheimerG??s symptoms within three to four years of accuracy. This breakthrough could facilitate early diagnosis and intervention for preventive treatments, significantly impacting clinical trials and potentially future individual patient care.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



